View source for BEACOPP

'''BEACOPP''' is a [[chemotherapy regimen]] for treatment of [[Hodgkin lymphoma]] developed by the German Hodgkin Study Group<ref>[http://en.ghsg.org/home German Hodgkin Study Group]</ref> used for patients in Stages > II or early (IA or IB) with unfavorable risk factors.<ref name=HD14>{{cite journal|last=von Tresckow|first=Bastian|title=Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial|journal=Journal of Clinical Oncology|date=March 20, 2012|volume=30|issue=9 |pages=907–913|doi=10.1200/JCO.2011.38.5807|pmid=22271480 |url=http://jco.ascopubs.org/content/30/9/907.full.pdf+html|accessdate=2013-01-24|display-authors=etal|doi-access=free}}</ref>
Patients typically receive treatment in cycles of 21 days with no drugs given on days 15–21.<ref>[http://jco.ascopubs.org/content/suppl/2012/01/23/JCO.2011.38.5807.DC1/385807_Redacted_trial_protocol.pdf See HD14 Redacted Trial Protocol, available at]</ref>
There also exists a more intensive regimen with cycles of 14 days. Usually a course of BEACOPP therapy consists of four, sometimes six to eight cycles, or in combination with ABVD.
In some countries BEACOPP still is experimental, in others (e.g. [[Germany]] and [[Austria]]) it is a standard therapy. In the United States, [[ABVD]] (or [[Stanford V]]) is generally given instead, because of the possibility of BEACOPP inducing more secondary neoplasias (such as leukemias), although the final results from a clinical trial (GHSG HD14) indicate that "there were no overall differences in treatment-related mortality or secondary malignancies" of BEACOPP relative to ABVD.<ref name="HD14"/>

Some{{who|date=May 2025}} believe that the BEACOPP regimen is used less often in the US for cost reasons:{{citation needed|date=May 2025}}{{original research inline|date=May 2025}}
* Twice as many infusion per cycle relative to [[ABVD]];
* Requirement for [[G-CSF]] support, which was under patent protection in the US until 2013 (as Neupogen by Amgen),<ref>{{cite web|title=Neupogen|url=http://www.fiercepharma.com/special-reports/neupogen|publisher=Fierce Pharma|accessdate=2013-01-24}}</ref>{{update needed|date=May 2025}} while that patent protection expired in the EU in 2008;<ref>{{cite web|title=Amgen And Its Biosimilar Competitors|work=Seeking Alpha |date=5 September 2012 |url=http://seekingalpha.com/article/846451-amgen-and-its-biosimilar-competitors|publisher=SeekingAlpha|accessdate=2013-01-24 |last1=Geschek |first1=Peter }}</ref>
* Higher likelihood of adverse events requiring hospitalization, such as infection or acute toxicity;

However,{{tone inline|date=May 2025}} BEACOPP delivers approximately 7% points success relative to ABVD for early unfavorable Hodgkin lymphoma (as measured five-year freedom from treatment failure)<ref name="HD14"/> and 12% points greater success relative to ABVD for advanced Hodgkin lymphoma (Stage IIB with risk factors or stages III and IV) as measured by seven-year freedom from treatment failure.<ref>{{cite journal|last=Viviani|first=Simonetta|title=ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned|journal=New England Journal of Medicine|date=July 21, 2011|volume=365|issue=3|pages=203–212|doi=10.1056/nejmoa1100340|display-authors=etal|pmid=21774708|doi-access=free}}</ref>

Predecessors of BEACOPP were [[COPP (chemotherapy)|COPP]] and (the earliest) [[MOPP (chemotherapy)|MOPP]].

== Dosing regimen ==

{| class="wikitable"
! Drug !! Base BEACOPP !! Dose-Escalated BEACOPP !! Method !! Cycle Day
|-
|[[Bleomycin|'''(B)'''leomycin]] || 10&nbsp;mg/m<sup>2</sup> || 10&nbsp;mg/m<sup>2</sup> || i.v. push || day 8
|-
|[[Etoposide|'''(E)'''toposide]] || 100&nbsp;mg/m<sup>2</sup>|| 200&nbsp;mg/m<sup>2</sup> || i.v. infusion || day 1–3
|-
|[[Adriamycin|'''(A)'''driamycin (doxorubicin)]] || 25&nbsp;mg/m<sup>2</sup>|| 35&nbsp;mg/m<sup>2</sup> || i.v. push|| day 1
|-
|[[Cyclophosphamide|'''(C)'''yclophosphamide]] || 650&nbsp;mg/m<sup>2</sup> || 1250&nbsp;mg/m<sup>2</sup> || i.v. infusion || day 1
|-
|[[Oncovin|'''(O)'''ncovin]]=[[Vincristine]] || 1.4&nbsp;mg/m<sup>2</sup> (max 2&nbsp;mg) || 1.4&nbsp;mg/m<sup>2</sup> (max 2&nbsp;mg) || i.v. infusion || day 8
|-
|[[procarbazine|'''(P)'''rocarbazine]] || 100&nbsp;mg/m<sup>2</sup> || 100&nbsp;mg/m<sup>2</sup> || orally || day 1–7
|-
|[[Prednisone|'''(P)'''rednisone]] || 40&nbsp;mg/m<sup>2</sup> || 40&nbsp;mg/m<sup>2</sup> || orally || day 1–14
|}

==See also==
* [[Stanford V]]
* [[ABVD]]

== References ==
{{Reflist}}



[[Category:Chemotherapy regimens used in lymphoma]]
[[Category:Hodgkin lymphoma]]